Linear porokeratosis and porokeratosis of Mibelli are characterized by sharply demarcated hyperkeratotic annular lesions with distinct keratotic edges but do not have eccrine gland
involvement on histopathology.
In these types, we are going to analyse the eccrine gland
Eccrine hidrocystomas are benign cystic lesions which originate from eccrine gland
ducts1 predominantly located on the face - eyelid and cheek regions.
It typically appears as a papule or solitary nodule, euchromatic or red in the sole or lateral border of the feet, corresponding to 2/3 of the cases; as with other eccrine gland
tumors, a pigmented variant of rare presentation exists (2,3) other sites affected are: the distal extremities, palms, and fingers, and less likely in the forearms, eyelids, thorax, scalp, external auditory canal, hip, gluteus, and abdomen (4-9).
The remaining 20% will need botulinum toxin A to block nerve endings from communicating with the smooth muscle in the eccrine gland
, which is required to push sweat out of the gland.
secretions from the fingers, hands, and feet are both organic and inorganic, but only organic materials are secreted from the sebaceous glands.
Main clinical feature of HED is sparse or absent eccrine gland
as well as hypotrichosis and oligodentia with peg-shaped teeth with incisor and/or canine teeth mainly affected which looks conical and pointed and sometimes is the only obvious abnormality.
Although not unique to KAs, histology may commonly show reactive proliferation of eccrine gland
ducts beneath the tumor lobules.
INTRODUCTION: Nodular hidradenoma (NH) is a rare benign sweat gland tumor which is traditionally believed to originate from the eccrine gland
Nodular hidradenoma is typically known to originate from eccrine glands
The eccrine glands
produce sweat and the sebaceous glands produce oil - so revving up the sweat glands doesn't actually turn on the oil glands involved in acne breakouts.
Hidradenocarcinoma originates in the eccrine glands
located in sun-exposed areas and accounts for approximately 6% of malignant eccrine tumors and <0.